MTX217

MTX217 is an orally bioavailable, small molecule dual inhibitor of the MET (mesenchymal-epithelial transition factor) and AXL receptor tyrosine kinases. Developed by Metis Therapeutics using its AI-driven drug discovery platform (AiTEM), MTX217 is designed to address resistance mechanisms in solid tumors, particularly non-small cell lung cancer (NSCLC). MET amplification and AXL upregulation are well-characterized bypass signaling pathways that confer resistance to third-generation EGFR inhibitors like osimertinib. By simultaneously targeting both kinases, MTX217 aims to provide a more comprehensive blockade of escape pathways, potentially improving outcomes for patients with MET- or AXL-driven malignancies or those who have progressed on prior targeted therapies. The drug is currently being evaluated in Phase 1 clinical trials for advanced solid tumors.